Affimed (AFMD) Reports Q4 Loss of EUR 0.22/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
Affimed Announces Financial Results for Fourth Quarter and Year End 2014
March 25, 2015 7:41 AM EDTHEIDELBERG, Germany, March 25, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage biopharmaceutical company developing highly targeted cancer immunotherapies, today reported financial results for the fourth quarter and year ended December 31, 2014.
"2014 has been a year in which the potential of cancer immunotherapies has been recognized by both clinical experts and the capital markets. Affimed has benefitted from our successful Nasdaq IPO, which has enabled us to advance our two lead bispecific TandAb antibody clinical programs that are based on recruiting immune cells," said Dr. Adi Hoess, CEO of... More



